Bioxcel Drug Patent Portfolio
Bioxcel owns 1 orange book drug protected by 14 US patents Given below is the list of Bioxcel's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11806334 | Non-sedating dexmedetomidine treatment regimens | 12 Jan, 2043 | Active |
| US11998528 | Non-sedating dexmedetomidine treatment regimens | 12 Jan, 2043 | Active |
| US12090140 | Non-sedating dexmedetomidine treatment regimens | 12 Jan, 2043 | Active |
| US12138247 | Non-sedating dexmedetomidine treatment regimens | 12 Jan, 2043 | Active |
| US12364683 | Non-Sedating Dexmedetomidine Treatment Regimens | 12 Jan, 2043 | Active |
| US11890272 | Non-sedating dexmedetomidine treatment regimens | 17 Jul, 2040 | Active |
| US11998529 | Non-sedating dexmedetomidine treatment regimens | 17 Jul, 2040 | Active |
| US12109196 | Non-sedating dexmedetomidine treatment regimens | 17 Jul, 2040 | Active |
| US10792246 | Film formulations containing dexmedetomidine and methods of producing them | 26 Jun, 2039 | Active |
| US11478422 | Film formulations containing dexmedetomidine and methods of producing them | 26 Jun, 2039 | Active |
| US11497711 | Film formulations containing dexmedetomidine and methods of producing them | 26 Jun, 2039 | Active |
| US11517524 | Film formulations containing dexmedetomidine and methods of producing them | 26 Jun, 2039 | Active |
| US11786508 | Use of sublingual dexmedetomidine for the treatment of agitation | 29 Dec, 2037 | Active |
| US11839604 | Use of sublingual dexmedetomidine for the treatment of agitation | 29 Dec, 2037 | Active |
Latest Legal Activities on Bioxcel's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bioxcel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 28 Oct, 2025 | US11806334 |
| Post Issue Communication - Certificate of Correction | 28 Oct, 2025 | US11998528 |
| Post Issue Communication - Certificate of Correction | 27 Oct, 2025 | US12138247 |
| Post Issue Communication - Certificate of Correction | 27 Oct, 2025 | US12090140 |
| Recordation of Patent Grant Mailed | 29 Jul, 2025 | US12364683 |
| Email Notification | 23 Jul, 2025 | US12364683 |
| Patent Issue Date Used in PTA Calculation | 22 Jul, 2025 | US12364683 |
| Patent eGrant Notification | 22 Jul, 2025 | US12364683 |
| Mail Patent eGrant Notification | 22 Jul, 2025 | US12364683 |
| Recordation of Patent eGrant | 22 Jul, 2025 | US12364683 |
| Email Notification | 10 Jul, 2025 | US12364683 |
| Issue Notification Mailed | 09 Jul, 2025 | US12364683 |
| Application Is Considered Ready for Issue | 20 Jun, 2025 | US12364683 |
| Dispatch to FDC | 20 Jun, 2025 | US12364683 |
| Issue Fee Payment Received | 18 Jun, 2025 | US12364683 |
Bioxcel's Family Patents
Bioxcel drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 47.4% of its total global patent coverage. Click
below to unlock the full patent family tree.
Bioxcel Drug List
Given below is the complete list of Bioxcel's drugs and the patents protecting them.
1. Igalmi
Igalmi is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11806334 | Non-sedating dexmedetomidine treatment regimens |
12 Jan, 2043
(16 years from now)
| Active |
| US11998528 | Non-sedating dexmedetomidine treatment regimens |
12 Jan, 2043
(16 years from now)
| Active |
| US12090140 | Non-sedating dexmedetomidine treatment regimens |
12 Jan, 2043
(16 years from now)
| Active |
| US12138247 | Non-sedating dexmedetomidine treatment regimens |
12 Jan, 2043
(16 years from now)
| Active |
| US12364683 | Non-Sedating Dexmedetomidine Treatment Regimens |
12 Jan, 2043
(16 years from now)
| Active |
| US11890272 | Non-sedating dexmedetomidine treatment regimens |
17 Jul, 2040
(14 years from now)
| Active |
| US11998529 | Non-sedating dexmedetomidine treatment regimens |
17 Jul, 2040
(14 years from now)
| Active |
| US12109196 | Non-sedating dexmedetomidine treatment regimens |
17 Jul, 2040
(14 years from now)
| Active |
| US10792246 | Film formulations containing dexmedetomidine and methods of producing them |
26 Jun, 2039
(13 years from now)
| Active |
| US11478422 | Film formulations containing dexmedetomidine and methods of producing them |
26 Jun, 2039
(13 years from now)
| Active |
| US11497711 | Film formulations containing dexmedetomidine and methods of producing them |
26 Jun, 2039
(13 years from now)
| Active |
| US11517524 | Film formulations containing dexmedetomidine and methods of producing them |
26 Jun, 2039
(13 years from now)
| Active |
| US11786508 | Use of sublingual dexmedetomidine for the treatment of agitation |
29 Dec, 2037
(11 years from now)
| Active |
| US11839604 | Use of sublingual dexmedetomidine for the treatment of agitation |
29 Dec, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Igalmi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List